C WorldWide Group Holding A S trimmed its holdings in shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 16.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,473 shares of the specialty pharmaceutical company’s stock after selling 4,585 shares during the quarter. C WorldWide Group Holding A S’s holdings in Supernus Pharmaceuticals were worth $1,182,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in the company. Icon Advisers Inc. Co. acquired a new position in Supernus Pharmaceuticals in the 3rd quarter valued at $3,877,000. WINTON GROUP Ltd raised its stake in Supernus Pharmaceuticals by 164.1% in the 3rd quarter. WINTON GROUP Ltd now owns 23,688 shares of the specialty pharmaceutical company’s stock valued at $1,193,000 after purchasing an additional 14,717 shares during the last quarter. Cambridge Investment Research Advisors Inc. acquired a new position in Supernus Pharmaceuticals in the 3rd quarter valued at $364,000. Baltimore Washington Financial Advisors Inc. acquired a new position in Supernus Pharmaceuticals in the 3rd quarter valued at $2,096,000. Finally, Chicago Equity Partners LLC raised its stake in Supernus Pharmaceuticals by 3.4% in the 3rd quarter. Chicago Equity Partners LLC now owns 89,305 shares of the specialty pharmaceutical company’s stock valued at $4,497,000 after purchasing an additional 2,965 shares during the last quarter. 99.10% of the stock is owned by institutional investors and hedge funds.
Several analysts have issued reports on SUPN shares. BidaskClub cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday. Piper Jaffray Companies restated a “hold” rating and issued a $46.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, July 25th. ValuEngine cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. Cantor Fitzgerald set a $57.00 target price on Supernus Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday. Finally, Jefferies Financial Group upped their target price on Supernus Pharmaceuticals from $55.00 to $58.00 and gave the company a “buy” rating in a report on Thursday, August 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $54.78.
Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.43 by $0.09. The company had revenue of $102.99 million during the quarter, compared to analysts’ expectations of $100.75 million. Supernus Pharmaceuticals had a return on equity of 30.57% and a net margin of 24.17%. The firm’s quarterly revenue was up 28.1% on a year-over-year basis. During the same period in the prior year, the business earned $0.29 EPS. As a group, equities analysts expect that Supernus Pharmaceuticals Inc will post 1.93 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by WKRB News and is owned by of WKRB News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.wkrb13.com/2018/11/08/supernus-pharmaceuticals-inc-supn-shares-sold-by-c-worldwide-group-holding-a-s.html.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.
Featured Story: How do investors use RSI to grade stocks?
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.